课题基金 / 基金详情

项目摘要

项目成果

Diane F Jelinek的其他基金

相似基金

相关文献

中文摘要
翻译
多发性骨髓瘤是一种普遍致命的疾病,其特征是骨髓中恶性浆细胞的积累。骨髓瘤细胞的生长特征与正常的终末期浆细胞形成鲜明对比。正常B细胞末端分化的分子调控尚不完全清楚,然而,人们认为这种调控涉及转录因子的激活,这些转录因子是驱动基因表达所必需的,这些基因的产物是分化表型的特异性产物。白细胞介素6 (IL-6)是驱动正常B细胞分化的一个重要外部信号;然而,它是在对细胞生长没有任何影响的情况下起作用的。相反,在侵袭性骨髓瘤患者中,IL-6作为恶性浆细胞的有效生长因子发挥作用。因此,我们假设骨髓瘤细胞对IL-6表现出改变的反应性,即生长而不是分化,并且由于这种IL-6反应性,IL-6刺激的基因表达发生了关键变化。关于IL-6介导的JAK/STAT和Ras-MAP激酶(Ras-MAPK)途径的激活存在大量信息,然而,这两种途径在IL-6介导的骨髓瘤细胞生长中的作用尚未确定。Pi之前已经建立了一个il -6应答的人类骨髓瘤细胞系小组,并且在正常人类B细胞和浆母细胞的研究方面也具有重要的专业知识。因此,她有独特的定位来分析这些特征明确的信号通路在骨髓瘤细胞生长中的作用。具体目的包括:(1)确定JAK/STAT激活通路在IL-6驱动的骨髓瘤细胞增殖中的重要性;(2)确定Ras/MAPK激活通路在IL-6驱动的骨髓瘤细胞增殖中的重要性;(3)利用差异显示逆转录聚合酶链反应和cDNA阵列分析,鉴定骨髓瘤中IL-6信号转导通路的遗传靶点。
英文摘要
Multiple myeloma is a universally fatal disease characterized by the accumulation of malignant plasma cells in the bone marrow. The growth characteristics of myeloma cells are in striking contrast with those of normal end-stage plasma cells. The molecular regulation of normal B cell terminal differentiation is incompletely understood, however, it is believed that this regulation involves the activation of transcription factors that are necessary to drive expression of genes whose products are specific to the differentiated phenotype. Interleukin 6 (IL-6) is an important example of an external signal that drives normal B cell differentiation; however, it does so in the absence of any effect on cell growth. In contrast, IL-6 functions as a potent growth factor for malignant plasma cells in patients with aggressive myeloma. We have, therefore, hypothesized that myeloma cells display an altered responsiveness to IL-6, i.e., growth rather than differentiation, and as a result of this IL-6 responsiveness, there are key changes in IL-6-stimulated gene expression. Considerable information exists regarding IL-6-mediated activation of the JAK/STAT and Ras-MAP kinase (Ras-MAPK) pathways, however, the role of either pathway has not been established in IL-6 mediated myeloma cell growth. The Pi previously has established a panel of IL-6-responsive human myeloma cell lines and also has significant expertise in the study of normal human B cells and plasmablasts. She is, therefore, uniquely positioned to analyze the role of these well-characterized signaling pathways in myeloma cell growth. The specific aims include: (l) to determine the importance of the JAK/STAT activation pathway in IL-6 driven myeloma cell proliferation; (2) to determine the importance of the Ras/MAPK activation pathway in IL-6 driven myeloma cell proliferation; and (3) to identify and characterize the genetic targets of IL-6 signal transduction pathway(s) in myeloma by utilizing differential display reverse transcription polymerase chain reaction and cDNA array analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression
  • 批准号:
    9102046
  • 项目类别:
  • 资助金额:
    $36.37万
  • 财政年份:
    2015
  • 负责人:
    Diane F Jelinek
  • 依托单位:
Developmental Research Program
  • 批准号:
    10270458
  • 项目类别:
  • 资助金额:
    $14.42万
  • 财政年份:
    2015
  • 负责人:
    Diane F Jelinek
  • 依托单位:
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression
  • 批准号:
    8937315
  • 项目类别:
  • 资助金额:
    $36.37万
  • 财政年份:
    2015
  • 负责人:
    Diane F Jelinek
  • 依托单位:
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression
  • 批准号:
    9281697
  • 项目类别:
  • 资助金额:
    $36.37万
  • 财政年份:
    2015
  • 负责人:
    Diane F Jelinek
  • 依托单位:
海外基金